Loading clinical trials...
Loading clinical trials...
A Phase 2, Open Label, Randomized Trial Evaluating Ixazomib Compared to Ixazomib-Lenalidomide Combination Maintenance Therapy for Frontline Multiple Myeloma Patients
Conditions
Interventions
Ixazomib
Lenalidomide
Locations
1
United States
James R Berenson, MD, Inc.
West Hollywood, California, United States
Start Date
March 1, 2019
Primary Completion Date
October 19, 2023
Completion Date
October 19, 2023
Last Updated
October 25, 2023
NCT05259553
NCT06348147
NCT05561049
NCT05558319
Lead Sponsor
Oncotherapeutics
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions